<DOC>
	<DOCNO>NCT01661179</DOCNO>
	<brief_summary>Open-label Study Evaluate Safety Tolerability Vandetanib 300 mg/day Japanese Patients Unresectable Locally Advanced Metastatic Medullary Thyroid Carcinoma .</brief_summary>
	<brief_title>Evaluate Safety Tolerability Vandetanib Japanese Patients With Medullary Thyroid Carcinoma</brief_title>
	<detailed_description>A Phase I/II , Open-label Study Evaluate Safety Tolerability Vandetanib 300 mg/day Japanese Patients Unresectable Locally Advanced Metastatic Medullary Thyroid Carcinoma</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<criteria>Written consent female male Japanese patient age 20 year . Evidence nonchildbearing status woman childbearing potential , postmenopausal status . Previous diagnosis unresectable , locally advanced metastatic , hereditary sporadic Medullary Thyroid Carcinoma ( MTC ) . Patients good overall health status ( World Health Organization ( WHO ) Performance status 02 ) . Patients appropriate renal condition confirm test result take part study . For patient measurable disease ( least one lesion , irradiate within 12 week study registration , long diameter equal 10mm ( lymph node minimum equal 15 mm ) CT MRI ) . Patients brain metastasis spinal cord compression . Patients significant abnormal ECG ( QTcB correction unmeasurable 480 m ) finding /or significant cardiac condition event , uncontrolled hypertension evidence severe lung disease . Abnormal electrolytes potassium , magnesium calcium , abnormal organ function decrease creatinine clearance . Patients significant abnormal laboratory finding ( include abnormal liver function test ( bilirubin 1.5xULRR , ALT , AST , ALP 2.5xULRR 5.0xULRR relate liver metastasis ) . Prior treatment ( major surgery , radiation therapy , chemotherapy , investigational drug ) receive within 28 day registration .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Medullary Thyroid Carcinoma</keyword>
	<keyword>Medullary Thyroid Cancer</keyword>
	<keyword>Vandetanib</keyword>
</DOC>